soul trial oral semaglutide cardiovascular outcomes nejm 2025 results 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants The SOUL Study - by

Description

Pricing starts near $199 plus supplies.

it requiring a doctors prescription

Background Initiation of Glucagon-Like Peptide-1 receptor agonists (GLP-1RA) in patients with type 2 diabetes (T2D) treated with levothyroxine may decrease the required levothyroxine dose due to weight loss or enhance levothyroxine absorption through delayed gastric emptying

Recent market analyses indicate that the GLP-1 segment in India has crossed approximately 1,000 crore in 2025, representing nearly 5 growth over the past five years

The diabetes medication Ozempic is sold out in many pharmacies throughout Portugal because it is being used for cosmetic weight loss purposes, along with another diabetes medication.